IfPA’s Patient Access Policy Blog

Perspective: My Clinical Trials Awareness Journey

The need for robust clinical trials participation is critical to women and men across this country, whether they know it or not.  I came to

Read More

New Video Explores Pay-for-Value Rx Pricing

Innovation comes at a price, one that health insurers may hesitate to pay.  While some patients reap a benefit from breakthrough drugs, others do not.

Read More

Non-Medical Switching May Increase Health Care Costs, New Study Finds

Opting for cheaper prescription drugs seems like an obvious way to cut health care costs.  The assumption has led health plans to employ utilization management

Read More

Can Yoga Solve America’s Opioid Abuse Crisis?

Could the solution to America’s opioid overdose crisis be as close as the nearest yoga studio?   A new study from the VA San Diego

Read More

New “Fast Facts” Examines Issue of Co-Pay Coupons

Are coupons that help patients afford their co-pays a help – or a hindrance – in the age of innovative but costly prescription medications?  A

Read More

Physicians Collaborate on Medicare Policy for Parkinson’s Patients

By Stuart Isaacson, MD Most all of us know someone living in a long-term care facility – a friend, a former neighbor, a family member.

Read More

IfPA Paper Weighs Access to Hepatitis C Cures for Prisoners

Nearly one in five Americans with hepatitis C spends time behind bars each year, making the prison system an opportune environment to test and cure

Read More

ICER Report Could Intensify Barriers for Heart Patients

Accessing innovative cardiovascular drugs may soon get harder. A new publication from the Institute for Clinical and Economic Review, a drug price analysis group, assigns

Read More

Experts Envision “Precision” Benefit Design

Health plans often use different levels of cost sharing to drive patients toward one medication over another. But is this practice fair, ethical or effective

Read More

Health Plan Coverage for Biosimilars Raises Questions

Health plans are embracing biosimilars, a new Avalere Health study reveals.  Eighty-one percent of health plans now cover at least one of the two biosimilars

Read More
Back to Top